KJ01
Pre-clinical- Indications
- Graft-versus-host disease
Company intelligence / Profile preview
Kiji’s lead products are iPSC-derived MSCs engineered with IL10 and CXCR4 to enhance immunomodulation and homing. Strong preclinical data support improved efficacy over traditional MSCs. The company has not yet reported clinical results but expects first-in-human studies in late–2025 for its GvHD program.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kiji Therapeutics.